Winton Group’s X4 Pharmaceuticals XFOR Stock Holding History

Winton Group’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.2K	Buy	14,400 +3,800	+36%	+$15.6K	﹤0.01%	1109
2026 Q1	$43.8K	Buy	+10,600	New	+$39.7K	﹤0.01%	1067

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Winton Group's XFOR Position: Q2 2026 in Review

Winton Group increased its X4 Pharmaceuticals (XFOR) stake by 36% in Q2 2026, buying an estimated $15.6K and bringing the position to 14,400 shares worth $67.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1109.

Winton Group first reported a position in XFOR in Q1 2026 and has held it in 2 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

Winton Group held 14,400 shares of X4 Pharmaceuticals worth $67.2K as of Q2 2026.
Winton Group bought 3,800 X4 Pharmaceuticals shares in Q2 2026, an estimated $15.6K.
X4 Pharmaceuticals made up ﹤0.01% of Winton Group's portfolio in Q2 2026, its #1109 holding.
Winton Group first reported a position in X4 Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.